2-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-7-(pyrimidin-2-yl)pyrimido[4',5':4,5]pyrimido[1,2-b]indazol-5(7H)-one | 1242150-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-{[3-fluoro-4-(4-methylpiperazin-1-yl)phenyl]amino}-7-(pyrimidin-2-yl)pyrimido[4',5':4,5]pyrimido[1,2-b]indazol-5(7H)-one
• 英文别名: 6-[3-Fluoro-4-(4-methylpiperazin-1-yl)anilino]-17-pyrimidin-2-yl-1,5,7,9,17-pentazatetracyclo[8.7.0.03,8.011,16]heptadeca-3,5,7,9,11,13,15-heptaen-2-one
• CAS: 1242150-83-9
• 化学式: C₂₇H₂₃FN₁₀O
• 分子量: 522.544
• InChiKey: LIIDGKQQHXDARI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  39
• 可旋转键数：
  4
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS
  申请人：Obrecht Daniel

  公开号：US20120202821A1

  公开（公告）日：2012-08-09

  Conformationally restricted, spatially defined 12-30 membered macrocyclic ring systems of type (I) are constituted by three distinct building blocks: an aromatic template a, a conformation modulator b and a spacer moiety c as detailed in the description and the claims. Macrocycles of type (I) are readily manufactured by parallel synthesis or combinatorial chemistry. They are designed to interact with specific biological targets. In particular, they show agonistic or antagonistic activity on the motilin receptor (MR receptor), on the serotonin receptor of subtype 5-HT 2B (5-HT 2B receptor), and on the prostaglandin F2•receptor (FP receptor). They are thus potentially useful for the treatment of hypomotility disorders of the gastrointestinal tract such as diabetic gastroparesis and constipation type irritable bowl syndrome; of CNS related diseases like migraine, schizophrenia, psychosis or depression; of ocular hypertension such as associated with glaucoma and preterm labour.

  构象受限、空间定义的12-30环大环环系统(I型)由三个不同的构建模块组成：芳香模板a、构象调节剂b和间隔基团c，如详细描述和索赔中所述。类型(I)的大环可通过并行合成或组合化学方法轻松制备。它们被设计用于与特定生物靶点相互作用。特别是，它们在胃动素受体(MR受体)、5-HT2B亚型的5-羟色胺受体(5-HT2B受体)和前列腺素F2受体(FP受体)上显示出激动或拮抗活性。因此，它们潜在地可用于治疗胃肠道低动力障碍，如糖尿病性胃轻瘫和便秘型肠易激综合征；中枢神经系统相关疾病，如偏头痛、精神分裂症、精神病或抑郁症；眼压增高，如青光眼和早产。
• PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE
  申请人：Goto Yasuhiro

  公开号：US20120134955A1

  公开（公告）日：2012-05-31

  The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R 1 means a —(C═O) a O b (C1-C6)alkyl group, a —(C═O) a O b (C2-C6)alkenyl group, a —(C═O) a O b (C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R 2 and R 3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a —(C═O) a O b (C1-C6)alkyl group or a group of —(C═O) a N(R 1e )R 2e ; R 4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee 1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.

  本发明提供一种新型的抗癌剂或增敏剂，用于癌症化疗或放疗。该化合物的一般式（I）如下：其中，A表示芳基或杂环基，或式（a）的基团；R1表示—（C═O）aOb（C1-C6）烷基，—（C═O）aOb（C2-C6）烯基，—（C═O）aOb（C3-C6）环烷基，芳基或杂环基；R2和R3各表示氢原子、卤素原子、羟基、羧基、—（C═O）aOb（C1-C6）烷基或—（C═O）aN（R1e）R2e基团；R4表示氢原子或（C1-C6）烷基等。该化合物具有出色的Wee 1-激酶抑制作用，因此在医学领域，特别是各种癌症治疗领域中非常有用。
• BETA-HAIRPIN PEPTIDOMIMETICS
  申请人：Obrecht Daniel

  公开号：US20120135942A1

  公开（公告）日：2012-05-31

  β-Hairpin peptidomimetics of the general formula Cyclo(-Xaa 1 -Xaa 2 -Xaa 3 -Cys 4 -Xaa 5 -Xaa 6 -Xaa 7 -Xaa 8 -Arg 9 -Tyr 10 -Cys 11 -Xaa 12 -Xaa 13 -Xaa 14 -Xaa 15 -Xaa 16 -), disulfide bond between Cys 4 and Cys11, and pharmaceutically acceptable salts thereof, with Xaa 1 , Xaa 2 , Xaa 3 , Xaa 5 , Xaa 6 , Xaa 7 , Xaa 8 , Xaa 12 , Xaa 13 , Xaa 14 , Xaa 15 and Xaa 16 being amino acid residues of certain types which are defined in the description and the claims, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immunosuppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These peptides can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
• US8288396B2
  申请人：——

  公开号：US8288396B2

  公开（公告）日：2012-10-16
• US8716242B2
  申请人：——

  公开号：US8716242B2

  公开（公告）日：2014-05-06